{"title":"Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.","authors":"M Salfinger, F M Kafader","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>One hundred and sixty clinical isolates of Mycobacterium tuberculois were tested for their sensitivity to pyrazinamide (PZA) using the conventional proportion method (Middlebrook 7H10 agar) and the results compared to the pyrazinamidase (PZase) activity of the strains. The correlation between strains susceptible to PZA and the production of PZase was 99%. None of the isolates were exclusively resistant to PZA. At present the rate of initial PZA resistance in Kanton Zurich is 0.6%.</p>","PeriodicalId":23821,"journal":{"name":"Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology","volume":"265 3-4","pages":"404-7"},"PeriodicalIF":0.0000,"publicationDate":"1987-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
One hundred and sixty clinical isolates of Mycobacterium tuberculois were tested for their sensitivity to pyrazinamide (PZA) using the conventional proportion method (Middlebrook 7H10 agar) and the results compared to the pyrazinamidase (PZase) activity of the strains. The correlation between strains susceptible to PZA and the production of PZase was 99%. None of the isolates were exclusively resistant to PZA. At present the rate of initial PZA resistance in Kanton Zurich is 0.6%.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
